Effect of antiviral therapy in patients with acute respiratory distress syndrome after CAP (community acquired pneumonia) and H1N1 infection on health-related quality of life (HRQoL) and cognitive performance

Effect of antiviral therapy in patients with acute respiratory distress syndrome after CAP (community acquired pneumonia) and H1N1 infection on health-related quality of life (HRQoL) and cognitive performance - FUCHS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011913

Enrollment

Registered

2017-04-19

Start date

2013-11-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute respiratory distress syndrome J80

Interventions

Group 1: H1N1 associated ARDS (acute respiratory distress syndrome). A retrospective analysis of duration of delirium (days), duration of mechanical Ventilation (days), duration of intensive care unit

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: acute respiratory distress Syndrome (ARDS); treatment period: 8/1/2009-09/03/2011

Exclusion criteria

Exclusion criteria: (1) no written informed consent (2) premorbid severe mental illness

Design outcomes

Primary

Measure	Time frame
The primary objective of this study is a retrospective analysis of clinical routine data concerning medication (cummulative dosage: opiate, benzodiazepnes, propofol, antopsychotics), cause of infection (H1N1, non-H1N1) duration of mechanical Ventilation (days) and length of ICU (days) and duration of Delirium (days).	—

Secondary

Measure	Time frame
HRQoL (health related quality of life) (SF-12), PTSD (posttraumatic stress disorder) (PTSS14; PDS), cognitive performance (CANTAB; VLMT) und physical capacity (6min walking test, spirometry) are evaluated in relation to duration of delirium (days). Measurement: 11/2013-4/2014.	—

Countries

Germany

Contacts

Public ContactMaria Deja

Charité Campus Benjamin Franklin

maria.deja@charite.de030-450551556

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026